Last updated: 3 March 2020 at 7:04pm EST

Venture Capital Vi, L.P.Ver... Net Worth




The estimated Net Worth of Venture Capital Vi, L.P.Ver... is at least $719 ezer dollars as of 3 March 2020. Venture Ver owns over 225,000 units of Passage Bio Inc stock worth over $718,681 and over the last 5 years Venture sold PASG stock worth over $0.

Venture Ver PASG stock SEC Form 4 insiders trading

Venture has made over 1 trades of the Passage Bio Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently Venture bought 225,000 units of PASG stock worth $4,050,000 on 3 March 2020.

The largest trade Venture's ever made was buying 225,000 units of Passage Bio Inc stock on 3 March 2020 worth over $4,050,000. On average, Venture trades about 225,000 units every 0 days since 2020. As of 3 March 2020 Venture still owns at least 933,352 units of Passage Bio Inc stock.

You can see the complete history of Venture Ver stock trades at the bottom of the page.



Insiders trading at Passage Bio Inc

Over the last 5 years, insiders at Passage Bio Inc have traded over $535,533 worth of Passage Bio Inc stock and bought 4,392,148 units worth $41,339,284 . The most active insiders traders include Liam Ratcliffe, Advisors Llc Orbi Med Capit... és Thomas Woiwode. On average, Passage Bio Inc executives and independent directors trade stock every 37 days with the average trade being worth of $92,858. The most recent stock trade was executed by Kathleen Borthwick on 10 February 2024, trading 4,000 units of PASG stock currently worth $3,080.



What does Passage Bio Inc do?

passage bio, inc., a genetic medicines company, develops transformative therapies for rare monogenic central nervous system (cns) diseases. the company develops pbgm01, which utilizes a proprietary, aavhu68 capsid to deliver to the brain and peripheral tissues a functional glb1 gene encoding lysosomal acid beta-galactosidase (ãŸ-gal) for infantile gm1; pbft02, which utilizes an aav1 capsid to deliver to the brain a functional granulin, or grn, gene encoding progranulin for the treatment of ftd caused by a deficiency of progranulin; and pbkr03, which utilizes a proprietary, aavhu68 capsid to deliver to the brain and peripheral tissues a functional galc gene encoding the hydrolytic enzyme galactosylceramidase, for infantile krabbe disease. it has a strategic research collaboration with the trustees of the university of pennsylvania's gene therapy program; and collaboration agreement, and a development services and clinical supply agreement with catalent maryland, inc. the company was fou



What does Passage Bio Inc's logo look like?

Passage Bio Inc logo

Complete history of Venture Ver stock trades at Passage Bio Inc

Dátum
#
Cég
Az érdekelt
Trans.
Tranzakció
Részvények száma Ár per részvény Teljes ár Részvények szíma után Forrás
3 Mar 2020 Venture Capital Vi, L.P.Ver...
Megvenni 225,000 $18.00 $4,050,000
3 Mar 2020
933,352


Passage Bio Inc executives and stock owners

Passage Bio Inc executives and other stock owners filed with the SEC include: